Queen’s Bench Division
Regina (Bayer plc)
v
NHS Darlington Clinical Commissioning Group and others
Regina (Novartis Pharmaceuticals UK Ltd)
v
NHS Darlington Clinical Commissioning Group and others
[2018] EWHC 2465 (Admin)
2018 July 10, 11, 13, 16;Sept 21
Whipple J
National Health ServiceMedicinal products Commissioning policyClinical commissioning groups adopting policy on treatment of eye conditionPolicy recommending use of particular product as preferred option for certain patientsMarket authorisation for product only covering use for cancer treatment whereas claimants’ rival products having market authorisation specific to opthalmic useProduct recommended in policy used “off-label” by dividing original vials into smaller doses for injection into eyeWhether policy lawfulWhether contrary to European Union law EU Treaty , art 4(3)EU Parliament and Council Directive 2001/83/EC (as amended by Parliament and Council Directive 2004/27/EC, art 1), arts 2(1), 3, 5, 6(1)
This content is available only to subscribers. If you have a subscription to this content, please log in.
If not, you can subscribe online, request a free trial, or contact ICLR by email at enquiries@iclr.co.uk or on +44 (0) 207 242 6471 to discuss further options.
JOHs should sign in via eLIS.

We use cookies on this website, you can read our Privacy and Cookies Policy. To use website as intended please Accept Cookies